CAJ | 학술논문

目的探讨改良小梁切除术治疗Ⅱ期新生血管性青光眼的疗效.方法取30例(30只眼)Ⅱ期新生血管性青光眼行术中应用丝裂霉素C和可拆缝线的小梁切除术.术后早期,术眼眼压≥15mmHg和滤过泡扁平,拆除可拆缝线.术后观察眼压、滤过泡、并发症.随访12～48个月.结果术前平均眼压(26.1±3.2)mmHg,最后一次随访时平均眼压(18.2 4±2.1)mmHg,两者之间差异有统计学意义(t=7.51,P<0.01).17只眼眼压<21mmHg,眼压控制成功率为56.7%.6只眼眼压>21mmHg,经局部应用降眼压药物后,眼压<21mmHg.17只眼术后有Ⅰ型或Ⅱ型功能性滤过泡.术后4只眼(13.3%)在一周内有Ⅰ度浅前房,未经处理,自行恢复.术后12只眼(40.0%)有前房积血,10只眼前房积血在术后7d内吸收.2只眼在术后15d内吸收.无其他并发症.结论改良小梁切除术能有效控制Ⅱ期新生血管性青光眼的眼压,术后无严重并发症,是一种安全、有效地Ⅱ期新生血管性青光眼的降眼压方法.
목적 탐토개량소량절제술치료Ⅱ기신생혈관성청광안적료효.방법 취30례(30지안)Ⅱ기신생혈관성청광안행술중응용사렬매소C화가탁봉선적소량절제술.술후조기,술안안압≥15mmHg화려과포편평,탁제가탁봉선.술후관찰안압、려과포、병발증.수방12～48개월.결과 술전평균안압(26.1±3.2)mmHg,최후일차수방시평균안압(18.2 4±2.1)mmHg,량자지간차이유통계학의의(t=7.51,P<0.01).17지안안압<21mmHg,안압공제성공솔위56.7%.6지안안압>21mmHg,경국부응용강안압약물후,안압<21mmHg.17지안술후유Ⅰ형혹Ⅱ형공능성려과포.술후4지안(13.3%)재일주내유Ⅰ도천전방,미경처리,자행회복.술후12지안(40.0%)유전방적혈,10지안전방적혈재술후7d내흡수.2지안재술후15d내흡수.무기타병발증.결론 개량소량절제술능유효공제Ⅱ기신생혈관성청광안적안압,술후무엄중병발증,시일충안전、유효지Ⅱ기신생혈관성청광안적강안압방법.
Objective To explore the clinical results of combined trabeculectomy with mitomycin C and removable sutures for stage Ⅱ neovascular glaucoma.Methods Thirty patients (30 eyes) in stage Ⅱ neovascular glaucoma were treated with trabeculectomy combined with mitomycin C and removable sutures. In the early postoperative period, removable sutures were removed when intraocular pressure (IOP) ≥15 mmHg with a flat bleb.The postoperative IOP, blebs and complications were recorded.The follow-up ranged from 12 to 48 months.Besults The mean preoperative IOP was (26.1± 3.2) mmHg, the mean postoperative IOP was (18.2± 2.1) mmHg, the difference was statistical significant (t=7.51, P<0.01 ).If success was defined as IOP <21mmHg without medication, the success rate of surgery was 56.7%.There were functional blebs in 17eyes. The incidence of hyphema was 40%, shallow anterior chamber was 13.3%, no other complications were ob-served.Conclusions Trabeculectomy with mitomycin C and removable sutures for stage Ⅱ neovascular glaucoma can effectively control IOP and do not induce serious complications.It is a safe and effective method of controlling IOP in stage Ⅱ of neovascular glaucoma.